Aridis Pharmaceuticals Inc (NASDAQ:ARDS) Given Consensus Recommendation of “Buy” by Brokerages

Shares of Aridis Pharmaceuticals Inc (NASDAQ:ARDS) have received a consensus recommendation of “Buy” from the seven ratings firms that are presently covering the company, MarketBeat.com reports. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $30.60.

ARDS has been the subject of several recent analyst reports. Northland Securities reaffirmed a “buy” rating and issued a $40.00 target price on shares of Aridis Pharmaceuticals in a research note on Friday, March 29th. Maxim Group reaffirmed a “buy” rating and issued a $25.00 target price on shares of Aridis Pharmaceuticals in a research note on Monday, April 1st. Finally, Zacks Investment Research raised shares of Aridis Pharmaceuticals from a “hold” rating to a “buy” rating and set a $12.00 target price for the company in a research note on Tuesday, April 2nd.

Shares of NASDAQ:ARDS opened at $11.10 on Wednesday. Aridis Pharmaceuticals has a 52 week low of $6.91 and a 52 week high of $13.85. The company has a market capitalization of $90.00 million and a P/E ratio of -1.58. The firm has a 50 day moving average price of $9.10.

Aridis Pharmaceuticals (NASDAQ:ARDS) last issued its earnings results on Tuesday, May 14th. The company reported ($0.99) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.87) by ($0.12). Aridis Pharmaceuticals had a negative net margin of 660.78% and a negative return on equity of 1,961.31%. The firm had revenue of $1.02 million during the quarter. On average, equities research analysts predict that Aridis Pharmaceuticals will post -3.11 earnings per share for the current year.

About Aridis Pharmaceuticals

Aridis Pharmaceuticals Inc, a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S.

See Also: What is a Reverse Stock Split?

Analyst Recommendations for Aridis Pharmaceuticals (NASDAQ:ARDS)

Receive News & Ratings for Aridis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aridis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.